Watson Sues FDA To Regain Exclusivity For Generic Actos

Law360, Washington (August 15, 2012, 2:43 PM EDT) -- Generic-drug maker Watson Laboratories Inc. sued the U.S. Food and Drug Administration on Wednesday in Washington federal court, claiming the agency is attempting to rob Watson of a 180-day marketing exclusivity period for a generic version of Takeda North America Inc.'s diabetes drug Actos.

Watson initially filed an abbreviated new drug application to market a generic form of Actos, or pioglitazone, in 2003. In March 2010, the company reached a settlement with Takeda that would allow it, Mylan Inc. and Ranbaxy Laboratories Ltd. to begin selling...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

WATSON LABORATORIES, INC. v. SEBELIUS et al


Case Number

1:12-cv-01344

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Amy Berman Jackson

Date Filed

August 15, 2012

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.